BioXcel Therapeutics (BTAI) EBITDA Margin (2022 - 2026)
BioXcel Therapeutics (BTAI) recorded quarterly EBITDA Margin of 4962.62% in Q1 2026, down 23.56% quarter-over-quarter from 4016.41% in Q4 2025, and up 104869.0% on a YoY basis from N/an in Q1 2025.
BioXcel Therapeutics (BTAI) EBITDA Margin (2022 - 2026) Analysis & Trends
BioXcel Therapeutics' EBITDA Margin history runs 5 years deep, the most recent figure standing at 4962.62% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 104869.0% year-over-year to 4962.62%; the TTM figure through Mar 2026 stood at 7438.97% (down 456743.0% YoY), while the FY2025 annual figure was 7859.97%, down 489240.0% from the prior year.
- EBITDA Margin was 4962.62% for Q1 2026 at BioXcel Therapeutics, down from 4016.41% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 1566.67% in Q2 2024 to a low of 28459.85% in Q3 2022.
- Historically, EBITDA Margin has averaged 10993.75% across 5 years, with a median of 7146.26% in 2024.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin surged 2070168 bps in 2024, then sank 1164333 bps in 2025.
- A 5-year view of EBITDA Margin shows it stood at 22224.37% in 2022, then soared by 76 bps to 5285.9% in 2023, then jumped by 46 bps to 2866.94% in 2024, then sank by 40 bps to 4016.41% in 2025, then decreased by 24 bps to 4962.62% in 2026.
- The last three EBITDA Margin figures came in at 4962.62% (Q1 2026), 4016.41% (Q4 2025), and 14518.37% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -1.01% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 22.74% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -170.35% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -16.25% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 21.55% |
| 10 | BioXcel Therapeutics | 25.46 Mn | 25.46 Mn | -77,000.00 | -4,962.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,962.62% |
| Dec 31, 2025 | -4,016.41% |
| Sep 30, 2025 | -14,518.37% |
| Jun 30, 2025 | -13,210.00% |
| Mar 31, 2025 | -6,011.31% |
| Dec 31, 2024 | -2,866.94% |
| Sep 30, 2024 | -7,146.26% |
| Jun 30, 2024 | -1,566.67% |
| Mar 31, 2024 | -4,151.72% |
| Dec 31, 2023 | -5,285.90% |
| Sep 30, 2023 | -14,163.34% |
| Jun 30, 2023 | -11,469.15% |
| Mar 31, 2023 | -24,853.40% |
| Dec 31, 2022 | -22,224.37% |
| Sep 30, 2022 | -28,459.85% |